<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01742078</url>
  </required_header>
  <id_info>
    <org_study_id>11952</org_study_id>
    <secondary_id>I2M-MC-GSDA</secondary_id>
    <nct_id>NCT01742078</nct_id>
  </id_info>
  <brief_title>A Study of LY2541546 in Healthy Postmenopausal Women</brief_title>
  <official_title>A Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY2541546 in Healthy Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if a single dose of LY2541546 has any side effects
      on the body and to determine how long and how much LY2541546 stays in the bloodstream of the
      body.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Day 1 through Day 85</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Curve Versus Time Curve from Time Zero to Infinity (AUC0-âˆž) of LY2541546</measure>
    <time_frame>Day 1 through Day 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD): Lumbar Spine Bone Mineral Density</measure>
    <time_frame>Predose (Day 1) and Postdose (Day 29 and 85)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic (PD): N-terminal Propeptide of Procollagen Type 1 (P1NP)</measure>
    <time_frame>Predose through Day 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity: The Number of Participants with Anti-LY2541546 Antibodies</measure>
    <time_frame>Predose (Day 1) and Postdose (Day 29 and 85)</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>7.5 mg LY2541546 - IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 7.5 mg LY2541546 administered intravenously (IV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>25 mg LY2541546 - IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 25 mg LY2541546 administered IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>75 mg LY2541546 - IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 75 mg LY2541546 administered IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>225 mg LY2541546 - IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 225 mg LY2541546 administered IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>750 mg LY2541546 - IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 750 mg LY2541546 administered IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>150 mg LY2541546 - SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 150 mg LY2541546 administered subcutaneous (SC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of placebo administered IV or SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>225 mg LY2541546 - IV, OL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 225 mg LY2541546 administered IV, open label (OL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>750 mg LY2541546 - IV, OL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 750 mg LY2541546 administered IV, OL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2541546 - IV</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>7.5 mg LY2541546 - IV</arm_group_label>
    <arm_group_label>25 mg LY2541546 - IV</arm_group_label>
    <arm_group_label>75 mg LY2541546 - IV</arm_group_label>
    <arm_group_label>225 mg LY2541546 - IV</arm_group_label>
    <arm_group_label>750 mg LY2541546 - IV</arm_group_label>
    <arm_group_label>225 mg LY2541546 - IV, OL</arm_group_label>
    <arm_group_label>750 mg LY2541546 - IV, OL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2541546 - SC</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>150 mg LY2541546 - SC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered IV or SC</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy postmenopausal females, as determined by medical history and physical
             examination

          -  Body mass index (BMI) at screening between 19.0 and 32.0 kilograms per square meter
             (kg/m^2), inclusive

          -  Acceptable Clinical laboratory test results, blood pressure and heart rate

          -  Have given written informed consent

          -  Additional Inclusion Criterion for Participants in Open Label Groups: Are currently
             taking or recently discontinued (not more than 3 months prior to study randomization)
             alendronate and have taken alendronate for at least 12 of the last 18 months

        Exclusion Criteria:

          -  Within 30 days of the initial dose of study drug, have received treatment with a drug
             that has not received regulatory approval for any indication

          -  Known allergies to LY2541546, its constituents, or related compounds

          -  Persons who have previously participated in this study

          -  History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal,
             endocrine, hematological, or neurological disorders

          -  History of or high risk for adverse outcome from bleeding, for example, transient
             ischemic attacks, cerebrovascular attacks, and ulcer disease

          -  Paget's disease, parathyroid disease, or thyroid disease

          -  Fracture of a long bone within 12 weeks of screening

          -  Regular use of known drugs of abuse and/or positive findings on urinary drug screening

          -  Evidence of human immunodeficiency virus (HIV), hepatitis C, hepatitis B and/or
             positive for anti-HIV antibodies, hepatitis C antibody, or hepatitis B surface antigen

          -  Current use of therapies for osteoporosis or use of hormone replacement therapy (HRT)
             within the previous 12 months

          -  Blood donation within the last month

          -  Participants who have an average weekly alcohol intake that exceeds 14 units per week

          -  Cigarette consumption of more than 10 cigarettes per day, or are unable or unwilling
             to refrain from nicotine during Clinical Research Unit (CRU) confinement

        Additional Exclusion Criterion for Participants in Double Blind Groups Only

          -  Have received bisphosphonates during the previous 24 months.

        Additional Exclusion Criterion for Participants in Open Label Groups

          -  Have received intravenous bisphosphonates within the previous 18 months
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2012</study_first_submitted>
  <study_first_submitted_qc>December 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2012</study_first_posted>
  <last_update_submitted>December 4, 2012</last_update_submitted>
  <last_update_submitted_qc>December 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Postmenopausal females</keyword>
  <keyword>Volunteers</keyword>
  <pending_results>
    <submitted>November 22, 2013</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>September 27, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

